Eli Lilly and Company (LLY) Stock Analysis 2026

Eli Lilly is a global pharmaceutical company focused on endocrinology, oncology, immunology, and neuroscience. The company has become the most valuable pharma company in the world thanks to its GLP-1 receptor agonist drugs — Mounjaro (for type 2 diabetes) and Zepbound (for obesity). These drugs represent the largest new drug class in pharmaceutical history, addressing a market of hundreds of millions of patients globally.

This chart shows how Eli Lilly and's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Eli Lilly and Company trades at a trailing P/E of 39.36x, generates $11.07B in free cash flow, runs a debt/equity ratio of 162.07, and converts shareholder equity into profit at a 102.3% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

27 analysts covering Eli Lilly and Company currently lean toward a Buy rating, with a mean 12-month price target of $1315.04 (+14.1% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate LLY's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

LLY is currently in a short-term downtrend, trading below its 50-day average of $1188.00 and above its 200-day average of $1060.62. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

LLY's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.